Banner Pharmacaps petitions
This article was originally published in The Tan Sheet
Executive Summary
Softgel manufacturer requests FDA permit ANDA filing for loperamide hydrochloride 2 mg soft gelatin capsules, which have "the same active ingredient, [are] of the same strength and [are] expected to have the same therapeutic effect" as McNeil's Imodium A-D tablets but differ in dosage form. In an 1Aug. 5 citizen petition, Banner requests permission "to make an alternate dosage form available for those who have difficulty swallowing tablets or simply prefer the alternative." Generic softgel would be limited to consumers 12 and older, while Imodium tablets target children over six, but would otherwise carry identical labeling. In separate 2Aug. 8 petition, Banner requests FDA amend the OTC laxatives monograph "to state that docusate calcium...is an interchangeable ingredient with docusate sodium...in proposed monograph combinations," noting the different salts of docusate are considered identical...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.